Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

Stock Information for Ampio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ampio Pharmaceuticals Inc.

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
Ampio Announces Voluntary Delisting and SEC Deregistration
Ampio Provides Update on Results from Pre-IND Enabling Studies
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.